Amgen Inc (AMGN) Gets a Hold Rating from RBC Capital

In a report released today, Kennen MacKay from RBC Capital maintained a Hold rating on Amgen Inc (AMGN), with a price target of $182. The company’s shares opened today at $201.92.

According to, MacKay is a 5-star analyst with an average return of 16.0% and a 56.9% success rate. MacKay covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Aimmune Therapeutics, and Abeona Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amgen Inc with a $211.90 average price target, implying a 4.9% upside from current levels. In a report issued on January 4, Citigroup also maintained a Hold rating on the stock with a $210 price target.

See today’s analyst top recommended stocks >>

Amgen Inc’s market cap is currently $129.1B and has a P/E ratio of 54.51. The company has a Price to Book ratio of 9.13.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

From Our Partners